With just over 100 days as CEO now under her belt, Catherine Owen Adams is looking to cruise rare disease-focused Acadia ...

TD Cowen analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $35.00.

$510,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Implementation of the Inflation ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

Acadia Pharmaceuticals has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for ...

Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals has submitted a Marketing ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ...

Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261-2872 [email protected] Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818) 395-3043 [email protected] Source ...